[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342360-105":59,"doc-detail-342360-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-practices-and-challenges-in-implementing-precision-medicine-for-upper-gastrointestinal-cancers-in-european-academic-centers-an-eortc-survey","Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey","","Surveying European academic oncology centers, the study evaluates how precision medicine is implemented for upper gastrointestinal cancers, focusing on molecular testing, timing, targeted therapy availability, and funding sources. Forty-five specialists from 41 institutions completed an EORTC-designed questionnaire to assess the use of molecular tumor boards and the translation of genomic results into treatment decisions. Routine testing for HER2, PD-L1, and mismatch repair is widespread, yet molecularly stratified treatment choices remain limited.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-practices-and-challenges-in-implementing-precision-medicine-for-upper-gastrointestinal-cancers-in-european-academic-centers-an-eortc-survey/342360/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-practices-and-challenges-in-implementing-precision-medicine-for-upper-gastrointestinal-cancers-in-european-academic-centers-an-eortc-survey/342360.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the EORTC survey in this study?","Question",{"text":112,"@type":113},"To assess current practices and challenges in implementing precision medicine technologies for upper gastrointestinal cancers across European academic centers, including molecular testing, therapy availability, and the role of molecular tumor boards.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many specialists and institutions participated in the survey?",{"text":117,"@type":113},"Forty-five oncology specialists from 41 European institutions completed the survey.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about molecular testing and MTB use?",{"text":121,"@type":113},"Most centers implemented routine testing for HER2, PD-L1, and mismatch repair, and molecular tumor boards were held regularly in many centers, often using ESCAT-based recommendations. However, treatment decisions based on comprehensive genetic testing were reported as limited.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342360,1791351531,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","ORIGINAL RESEARCH ARTICLES  \nCurrent practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey  \nM. Alsina1, 2􀀁, A. E. Huerta2, F. Lordick3, S. Verschueren4, M. Moehler5, E. Fontana6, E. Smyth7, F. Sclafani8, A. D. Wagner9,  \nL. Rimassa10 , 11, A. Lamarca12, C. Neuzillet13 , 14 & R. Obermannová15 􀀁  \n1Department of Medical Oncology, Hospital Universitario de Navarra (HUN), Pamplona; 2Translational Medical Oncology Unit, Navarrabiomed e Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain; 3Department of Medicine (Oncology, Gastroenterology, Hepatology, Pulmonology), University of Leipzig Medical Center and Comprehensive Cancer Center Central Germany (CCCG), Leipzig, Germany; 4The European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium; 5Department of Medicine, Research Center for Immunotherapy (FZI), Johannes Gutenberg-University Clinic, Mainz, Germany; 6Sarah Cannon Research Institute UK, London; 7Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK; 8Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium; 9Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 10Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; 11Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; 12Department of Oncology e OncoHealth Institute e Instituto de Investigaciones Sanitarias FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain; 13GI Oncology, Department of Medical Oncology, Curie Institute, Versailles Saint Quentin University, Saint-Cloud; 14UMR144, Team Radvanyi, Curie Institute Research Center, Paris, France; 15Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic  \nAvailable online 8 August 2024  \nBackground: Precision oncology is gaining momentum in managing patients with gastrointestinal cancers. This study examines the implementation of personalized medicine technologies in upper gastrointestinal (UGI) oncology across European academic centers.  \nMaterial and methods: Forty-ﬁve oncology specialists from 41 European institutions completed a survey designed by the Personalized Medicine Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Working Group, providing insights into molecular testing, timing, availability of targeted therapies, funding sources, and utilization of molecular tumor boards (MTBs) for patients with UGI cancers. Frequencies and percentages were calculated.  \nResults: Routine testing for human epidermal growth factor receptor 2 (HER2, 100%), programmed death-ligand 1 (PDL1, 89%), and DNA mismatch repair (MMR, 91%) is implemented in most centers. Comprehensive gene panels on tumor tissue are frequently utilized, especially in biliary tract cancer, with almost all centers incorporating them into routine practice. Blood-based sequencing is increasingly employed, and half of centers carry out comprehensive gene panels for circulating tumor DNA analyses. MTBs are regularly held in 76% of centers, predominantly utilizing ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)-based recommendations for tissue molecular alterations. The translation of genomic information into prescribed treatments remains limited, however, with the majority of centers reporting w25% of molecularly stratiﬁed treatment decisions following comprehensive genetic testing. Conclusion: This survey provides important insights into current personalized medicine practice in European academic clinical centers for UGI oncology. Despite widespread adoption of molecular testing and implementation of MTBs, further efforts are needed to optimize the integration of personalized medicine in","cbCaioyPyPyxmaRR","https://ap.wps.com/l/cbCaioyPyPyxmaRR","pdf",685618,"English","# Background\n# Material and methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What was the purpose of the EORTC survey in this study?\",\"answer\":\"To assess current practices and challenges in implementing precision medicine technologies for upper gastrointestinal cancers across European academic centers, including molecular testing, therapy availability, and the role of molecular tumor boards.\"},{\"question\":\"How many specialists and institutions participated in the survey?\",\"answer\":\"Forty-five oncology specialists from 41 European institutions completed the survey.\"},{\"question\":\"What did the study find about molecular testing and MTB use?\",\"answer\":\"Most centers implemented routine testing for HER2, PD-L1, and mismatch repair, and molecular tumor boards were held regularly in many centers, often using ESCAT-based recommendations. However, treatment decisions based on comprehensive genetic testing were reported as limited.\"}]","Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey | PDF",1790046269,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1aab2290716d1e60077449a5ca008118.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3546f8d9e3b54aa541e40e1cd3735006.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3a8b38362426f414d27657f8033794c.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8e1a29e4d0ad8fb77e5f4154898e4da.webp",980,1265]